Cerebrovia Therapeutics Ltd is developing mechanism-based CNS therapeutics for patients with persistent neurological symptoms following concussion and related trauma-linked neurological conditions.

Cerebrovia’s therapeutic approach is designed to move beyond symptom management by addressing post-concussive neurovascular, vestibular and neuronal dysfunction.

With a patent-protected approach, defined biological rationale and human clinical case evidence, Cerebrovia is advancing toward controlled clinical evaluation and engaging investors and strategic partners.

Patent-protected approach | Human clinical case evidence | First-in-class potential